ImmunoTherapeutics Inc. said Tuesday that it has filed aninvestigational new drug (IND) application for its secondimmunomodulator, Theramide, for treating cancer and certaininfectious diseases.
The drug is a lipophilic disaccharide peptide that is a longer-acting substance than ImmunoTherapeutics' firstimmunomodulator, ImmTher, and it can be given without aliposome carrier. ImmunoTherapeutics of Moorhead, Minn.,said Theramide forms small liposome-like structures known asmini-micelles, which have the same tissue distribution as theliposome incorporated formulation.
The company noted that Theramide is not a substitute forImmTher since the two have different profiles of activity andare suited for different indications. ImmTher is in Phase IItrials for treatment of colorectal cancer. -- Brenda Sandburg
(c) 1997 American Health Consultants. All rights reserved.